NPM1 and acute myeloid leukemia: Furthermore, secondary AML is a heterogeneous group even with regard to adverse prognosis [52,53,54,55,56,57], where at least NPM1-mutated chemotherapy-associated secondary AML seem to have a better prognosis, similar to de novo NPM1-mutated AML [91,92,93].